InvestmentJun 3, 2026, 04:13 PM
Mineralys Therapeutics Prices $150M Underwritten Common Stock Offering
AI Summary
Mineralys Therapeutics priced an underwritten offering of 5,660,378 shares of its common stock at $26.50 per share, expecting gross proceeds of approximately $150.0 million and net proceeds of about $142.5 million. The offering, managed by BofA Securities, Goldman Sachs & Co. LLC, and Evercore Group L.L.C., is expected to close on June 4, 2026. The company plans to use the net proceeds to fund a portion of a $200.0 million upfront payment for the repurchase of a royalty obligation under its license agreement with Tanabe Pharma Corporation, complementing a recently announced $500 million committed debt facility.
Key Highlights
- Priced underwritten offering of 5,660,378 shares of common stock.
- Offering price set at $26.50 per share.
- Expected aggregate gross proceeds of approximately $150.0 million.
- Expected net proceeds of approximately $142.5 million after expenses.
- Proceeds to fund a portion of $200.0 million royalty obligation repurchase.
- Offering expected to close on June 4, 2026.
- Underwriters include BofA Securities, Goldman Sachs & Co. LLC, and Evercore Group L.L.C.
- Follows a $500 million committed debt facility announcement.
Price Impact
More from MLYS